SIRT1 rs10823108 and FOXO1 rs17446614 responsible for genetic susceptibility to diabetic nephropathy

[1]  G. Qin,et al.  FoxO1 Promotes Mitophagy in the Podocytes of Diabetic Male Mice via the PINK1/Parkin Pathway , 2017, Endocrinology.

[2]  K. Al-Rubeaan,et al.  Assessment of the diagnostic value of different biomarkers in relation to various stages of diabetic nephropathy in type 2 diabetic patients , 2017, Scientific Reports.

[3]  C. J. Everett,et al.  Exposure to DDT and diabetic nephropathy among Mexican Americans in the 1999-2004 National Health and Nutrition Examination Survey. , 2017, Environmental pollution.

[4]  F. Wang,et al.  Incidence, Development, and Prognosis of Diabetic Kidney Disease in China: Design and Methods , 2017, Chinese medical journal.

[5]  S. McGhee,et al.  Effectiveness of the multidisciplinary Risk Assessment and Management Program for Patients with Diabetes Mellitus (RAMP-DM) for diabetic microvascular complications: A population-based cohort study. , 2016, Diabetes & metabolism.

[6]  K. Fukuo,et al.  Association of Postbreakfast Triglyceride and Visit-to-Visit Annual Variation of Fasting Plasma Glucose with Progression of Diabetic Nephropathy in Patients with Type 2 Diabetes , 2016, Journal of diabetes research.

[7]  L. Donini,et al.  Circulating SIRT1 inversely correlates with epicardial fat thickness in patients with obesity. , 2016, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[8]  G. Paolisso,et al.  Moderate-intensity statin therapy seems ineffective in primary cardiovascular prevention in patients with type 2 diabetes complicated by nephropathy. A multicenter prospective 8 years follow up study , 2016, Cardiovascular Diabetology.

[9]  J. Coresh,et al.  Trends in Chronic Kidney Disease in China. , 2016, The New England journal of medicine.

[10]  John M Lachin,et al.  Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. , 2016, The New England journal of medicine.

[11]  G. Qin,et al.  Overexpression of FOXO1 ameliorates the podocyte epithelial-mesenchymal transition induced by high glucose in vitro and in vivo. , 2016, Biochemical and biophysical research communications.

[12]  G. Qin,et al.  Activation of FoxO1/ PGC-1α prevents mitochondrial dysfunction and ameliorates mesangial cell injury in diabetic rats , 2015, Molecular and Cellular Endocrinology.

[13]  J. Hirschhorn,et al.  Genetic Evidence for a Causal Role of Obesity in Diabetic Kidney Disease , 2015, Diabetes.

[14]  C. Bogardus,et al.  Assessing FOXO1A as a Potential Susceptibility Locus for Type 2 Diabetes and Obesity in American Indians , 2015, Obesity.

[15]  S. Chakrabarti,et al.  SIRT1 reduction causes renal and retinal injury in diabetes through endothelin 1 and transforming growth factor β1 , 2015, Journal of cellular and molecular medicine.

[16]  Peiqing Liu,et al.  Polydatin promotes Nrf2-ARE anti-oxidative pathway through activating Sirt1 to resist AGEs-induced upregulation of fibronetin and transforming growth factor-β1 in rat glomerular messangial cells , 2015, Molecular and Cellular Endocrinology.

[17]  Guofang Wu,et al.  MiR-15a/b promote adipogenesis in porcine pre-adipocyte via repressing FoxO1. , 2014, Acta biochimica et biophysica Sinica.

[18]  L. Guarente,et al.  SIRT1 and other sirtuins in metabolism , 2014, Trends in Endocrinology & Metabolism.

[19]  Xueqing Yu,et al.  Diabetic retinopathy in predicting diabetic nephropathy in patients with type 2 diabetes and renal disease: a meta-analysis , 2013, Diabetologia.

[20]  H. Maegawa,et al.  Anti-aging molecule, Sirt1: a novel therapeutic target for diabetic nephropathy , 2013, Archives of pharmacal research.

[21]  S. Kume,et al.  Sirtuins and renal diseases: relationship with aging and diabetic nephropathy , 2012, Clinical science.

[22]  N. Zhang,et al.  The effect of resveratrol on FoxO1 expression in kidneys of diabetic nephropathy rats , 2012, Molecular Biology Reports.

[23]  C. Sheline.  Involvement of SIRT1 in Zn2+, Streptozotocin, Non-Obese Diabetic, and Cytokine-Mediated Toxicities of β-cells. , 2012, Journal of diabetes & metabolism.

[24]  Bhaskar Ponugoti,et al.  Role of Forkhead Transcription Factors in Diabetes-Induced Oxidative Stress , 2012, International Journal of Experimental Diabetes Research.

[25]  Bin Wang,et al.  Bufalin inhibits platelet-derived growth factor-BB-induced mesangial cell proliferation through mediating cell cycle progression. , 2011, Biological & pharmaceutical bulletin.

[26]  J. Navarro-González,et al.  Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy , 2011, Nature Reviews Nephrology.

[27]  Yusuke Nakamura,et al.  Association between single nucleotide polymorphisms within genes encoding sirtuin families and diabetic nephropathy in Japanese subjects with type 2 diabetes , 2011, Clinical and Experimental Nephrology.

[28]  M. Laakso,et al.  Association of common genetic variation in the FOXO1 gene with beta-cell dysfunction, impaired glucose tolerance, and type 2 diabetes. , 2009, The Journal of clinical endocrinology and metabolism.

[29]  M. Stumvoll,et al.  A SNP haplotype of the forkhead transcription factor FOXO1A gene may have a protective effect against type 2 diabetes in German Caucasians. , 2007, Diabetes & metabolism.

[30]  C. Kahn,et al.  SIRT2 regulates adipocyte differentiation through FoxO1 acetylation/deacetylation. , 2007, Cell metabolism.

[31]  L. Guarente,et al.  SIRT1 Inhibits Transforming Growth Factor β-Induced Apoptosis in Glomerular Mesangial Cells via Smad7 Deacetylation* , 2007, Journal of Biological Chemistry.

[32]  S. Gabriel,et al.  The Structure of Haplotype Blocks in the Human Genome , 2002, Science.

[33]  M. Xiong,et al.  Haplotypes vs single marker linkage disequilibrium tests: what do we gain? , 2001, European Journal of Human Genetics.

[34]  E. Seaquist,et al.  Familial clustering of diabetic kidney disease. Evidence for genetic susceptibility to diabetic nephropathy. , 1989, The New England journal of medicine.

[35]  A. Krolewski,et al.  The genetic risk of kidney disease in type 2 diabetes. , 2013, The Medical clinics of North America.

[36]  Kirsten L. Johansen,et al.  US Renal Data System 2011 Annual Data Report , 2012 .